These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 9764780)
1. Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy. Raboud JM; Montaner JS; Conway B; Rae S; Reiss P; Vella S; Cooper D; Lange J; Harris M; Wainberg MA; Robinson P; Myers M; Hall D AIDS; 1998 Sep; 12(13):1619-24. PubMed ID: 9764780 [TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. Montaner JS; Reiss P; Cooper D; Vella S; Harris M; Conway B; Wainberg MA; Smith D; Robinson P; Hall D; Myers M; Lange JM JAMA; 1998 Mar; 279(12):930-7. PubMed ID: 9544767 [TBL] [Abstract][Full Text] [Related]
3. Meta-analysis of two randomized controlled trials comparing combined zidovudine and didanosine therapy with combined zidovudine, didanosine, and nevirapine therapy in patients with HIV. INCAS study team. Raboud JM; Rae S; Vella S; Harrigan PR; Bucciardini R; Fragola V; Ricciardulli D; Montaner JS J Acquir Immune Defic Syndr; 1999 Nov; 22(3):260-6. PubMed ID: 10770346 [TBL] [Abstract][Full Text] [Related]
4. Suppression of plasma virus load below the detection limit of a human immunodeficiency virus kit is associated with longer virologic response than suppression below the limit of quantitation. Raboud JM; Rae S; Hogg RS; Yip B; Sherlock CH; Harrigan PR; O'Shaughnessy MV; Montaner JS J Infect Dis; 1999 Oct; 180(4):1347-50. PubMed ID: 10479170 [TBL] [Abstract][Full Text] [Related]
5. Predictive factors influencing peak viral load drop in response to nucleoside reverse transcriptase inhibitors in antiretroviral-naive HIV-1-infected patients. Vidal C; García F; Gatell JM; Leal M; Clotet B; Pumarola T; Miró JM; Mallolas J; Ruiz L; Cruceta A; Tortajada C J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Sep; 19(1):55-60. PubMed ID: 9732070 [TBL] [Abstract][Full Text] [Related]
6. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. D'Aquila RT; Hughes MD; Johnson VA; Fischl MA; Sommadossi JP; Liou SH; Timpone J; Myers M; Basgoz N; Niu M; Hirsch MS Ann Intern Med; 1996 Jun; 124(12):1019-30. PubMed ID: 8633815 [TBL] [Abstract][Full Text] [Related]
7. The VIRGO study: nevirapine, didanosine and stavudine combination therapy in antiretroviral-naive HIV-1-infected adults. Raffi F; Reliquet V; Ferré V; Arvieux C; Hascoet C; Bellein V; Besnier JM; Breux JP; Garré M; May T; Molina JM; Perré P; Raguin G; Rozenbaum W; Zucman D Antivir Ther; 2000 Dec; 5(4):267-72. PubMed ID: 11142621 [TBL] [Abstract][Full Text] [Related]
8. AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients. AIDS; 2000 Mar; 14(4):367-74. PubMed ID: 10770538 [TBL] [Abstract][Full Text] [Related]
9. HIV-1 RNA response to antiretroviral treatment in 1280 participants in the Delta Trial: an extended virology study. ; AIDS; 1999 Jan; 13(1):57-65. PubMed ID: 10207545 [TBL] [Abstract][Full Text] [Related]
10. Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort. Paris D; Ledergerber B; Weber R; Jost J; Flepp M; Opravil M; Ruef C; Zimmerli S AIDS Res Hum Retroviruses; 1999 Dec; 15(18):1631-8. PubMed ID: 10606086 [TBL] [Abstract][Full Text] [Related]
11. A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study). Podzamczer D; Ferrer E; Consiglio E; Gatell JM; Perez P; Perez JL; Luna E; González A; Pedrol E; Lozano L; Ocaña I; Llibre JM; Casiró A; Aranda M; Barrufet P; Martínez-Lacasa J; Miró JM; Badía X; Casado A; Lupo S; Cahn P; Maños M; Estela J Antivir Ther; 2002 Jun; 7(2):81-90. PubMed ID: 12212928 [TBL] [Abstract][Full Text] [Related]
12. Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy. INCAS Study Group. Pakker NG; Kroon ED; Roos MT; Otto SA; Hall D; Wit FW; Hamann D; van der Ende ME; Claessen FA; Kauffmann RH; Koopmans PP; Kroon FP; ten Napel CH; Sprenger HG; Weigel HM; Montaner JS; Lange JM; Reiss P; Schellekens PT; Miedema F AIDS; 1999 Feb; 13(2):203-12. PubMed ID: 10202826 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of didanosine and lamivudine both once daily plus indinavir in human immunodeficiency virus-infected patients. de Mendoza C; Soriano V; Pérez-Olmeda M; Rodríguez-Rosado R; González-Lahoz J J Hum Virol; 2000; 3(6):335-40. PubMed ID: 11100914 [TBL] [Abstract][Full Text] [Related]
15. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial. Staszewski S; Keiser P; Montaner J; Raffi F; Gathe J; Brotas V; Hicks C; Hammer SM; Cooper D; Johnson M; Tortell S; Cutrell A; Thorborn D; Isaacs R; Hetherington S; Steel H; Spreen W; JAMA; 2001 Mar; 285(9):1155-63. PubMed ID: 11231744 [TBL] [Abstract][Full Text] [Related]
16. Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. AIDS Clinical Trials Group Protocol 320. Demeter LM; Hughes MD; Coombs RW; Jackson JB; Grimes JM; Bosch RJ; Fiscus SA; Spector SA; Squires KE; Fischl MA; Hammer SM Ann Intern Med; 2001 Dec; 135(11):954-64. PubMed ID: 11730396 [TBL] [Abstract][Full Text] [Related]
17. Comparison of twice-daily stavudine plus once- or twice-daily didanosine and nevirapine in early stages of HIV infection: the scan study. García F; Knobel H; Sambeat MA; Arrizabalaga J; Aranda M; Romeu J; Dalmau D; Segura F; Gomez-Sirvent JL; Ferrer E; Cruceta A; Gallart T; Pumarola T; Miró JM; Gatell JM; AIDS; 2000 Nov; 14(16):2485-94. PubMed ID: 11101059 [TBL] [Abstract][Full Text] [Related]
18. A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study. García F; Romeu J; Grau I; Sambeat MA; Dalmau D; Knobel H; Gomez-Sirvent JL; Arrizabalaga J; Cruceta A; Clotet BG; Podzamczer D; Pumarola T; Gallart T; O'Brien WA; Miró JM; Gatell JM AIDS; 1999 Dec; 13(17):2377-88. PubMed ID: 10597779 [TBL] [Abstract][Full Text] [Related]
19. Effect of lamivudine in HIV-infected persons with prior exposure to zidovudine/didanosine or zidovudine/zalcitabine. Albrecht MA; Hughes MD; Liou SH; Katzenstein DA; Murphy R; Balfour HH; Para MF; Valdez H; Hammer SM; AIDS Res Hum Retroviruses; 2000 Sep; 16(14):1337-44. PubMed ID: 11018853 [TBL] [Abstract][Full Text] [Related]
20. A randomized double-blind trial of the addition of lamivudine or matching placebo to current nucleoside analogue reverse transcriptase inhibitor therapy in HIV-infected children: the PENTA-4 trial. Paediatric European Network for Treatment of AIDS. AIDS; 1998 Oct; 12(14):F151-60. PubMed ID: 9792371 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]